Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 706 clinical trials
featured
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer  

Primary Objective: To determine whether Amcenestrant (SAR439859) in combination with palbociclib improvesprogression free survival (PFS) when compared with letrozole in combination with palbociclib in participants with ER+, HER2- advanced breast cancer who have not received any prior systemic anticancer therapies for advanced disease. Secondary Objective: To compare the overall survival …

erbb2
breast cancer
measurable disease
letrozole
palbociclib
  • 23 views
  • 09 Sep, 2021
  • 4 locations
featured
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.  

cancer
metastatic cancer
primary cancer
FGFR2
  • 173 views
  • 25 Aug, 2021
  • 146 locations
featured
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

lung carcinoma
epidermal growth factor
lung cancer
epidermal growth factor receptor
EGFR
  • 100 views
  • 23 Nov, 2020
  • 1 location
featured
TOL2506A

Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

erbb2
epidermal growth factor receptor
epidermal growth factor
EGFR
growth factor
  • 0 views
  • 29 Jul, 2021
  • 1 location
featured
  • 74 views
  • 08 Nov, 2020
  • 1 location
featured
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

growth factor. The growth factor (granulocyte colony stimulating factor) is designed to increase the production of donor stem cells. In the second step white blood cell lymphocytes are removed from

  • 194 views
  • 22 Dec, 2020
  • 1 location
featured
A Randomized Trial of Sirolimus (Rapamune) for Relapse Prevention in Patients with Severe Aplastic Anemia Responsive to Immunosuppressive Therapy

Background: People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or platelets. Their body's immune system stops the bone marrow from making these cells. The treatment cyclosporine leads to better blood counts. But when this treatment is stopped, the disease may return in 1 …

anemia studies
anemia
myelodysplastic syndrome (mds)
myelodysplastic syndromes
aplastic anemia
  • 61 views
  • 22 Dec, 2020
  • 1 location
featured
Diabetic Neuropathy in Type 1 and 2 Diabetics

Diabetic Neuropathy in Type 1 and 2 Diabetics

  • 2904 views
  • 25 Mar, 2021
  • 1 location
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial

The study is an double blind, randomized, multicenter phase 3 trial. The efficacy analyses are based on 570 Chinese patients with RAS wt mCRC treated with mFOLFOX-6 cetuximab. Study treatment continues until disease progression or unacceptable toxicity (ie, not for a fixed number of courses). The primary endpoint of the …

platelet count
adenocarcinoma
modified folfox6
adenocarcinoma of colon
measurable disease
  • 7 views
  • 22 Jan, 2021
  • 1 location
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor

adjuvant chemotherapy
pembrolizumab
transitional cell carcinoma
vinflunine
growth factor
  • 271 views
  • 19 Sep, 2021
  • 594 locations